Back to Search Start Over

Firibastat: A Novel Brain Aminopeptidase Inhibitor - A New Era of Antihypertensive therapy.

Authors :
Gupta R
Alcantara R
Popli T
Tariq U
Sood A
Mahajan S
Ayele H
Rajeswaran Y
Vyas AV
Source :
Current problems in cardiology [Curr Probl Cardiol] 2022 Sep; Vol. 47 (9), pp. 100859. Date of Electronic Publication: 2021 Apr 03.
Publication Year :
2022

Abstract

Global incidence and prevalence of hypertension continues to increase and remains a significant challenge. The ever-increasing number of cases are due to comorbid conditions such as obesity and diabetes, as well as lifestyle indiscretions such as excessive salt intake. Hypertension, congestive heart failure, and kidney disease are all conditions resulting from abnormal Renin-Angiotensin-Aldosterone activation and adverse remodeling. Firibastat, a novel Brain Aminopeptidase inhibitor, may be able to help achieve blood pressure control in those with resistant hypertension. In this review article, we will discuss the biochemical pathway of firibastat and various trials assessing drug efficacy in animals and humans. This drug has the potential to curb the risk of uncontrolled hypertension and help improve long term cardiovascular morbidity and mortality.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1535-6280
Volume :
47
Issue :
9
Database :
MEDLINE
Journal :
Current problems in cardiology
Publication Type :
Academic Journal
Accession number :
33994025
Full Text :
https://doi.org/10.1016/j.cpcardiol.2021.100859